Special Report: Creso Pharma has secured an Australian import licence and a distribution deal for its cannaQIX®50 treatment.

Creso Pharma (ASX:CPH) has added Australia to its list of countries, securing an import permit and a deal to distribute its cannaQIX®50 medical cannabis lozenge here.

This follows a similar deal to sell the medical cannabis treatment in Brazil which they signed a month ago.

Burleigh Heads Cannabis will distribute the product in Australia, allowing Creso to geographically expand the distribution of its innovative therapeutic medicinal cannabis products into Australia.

Both Creso and Burleigh Heads have received regulatory acceptance for the first shipment of Creso’s flag-ship medicinal cannabis product which will be imported in Q3 2019.

“We are delighted to announce the formal signing of this milestone distribution agreement for Australia. Burleigh Heads Cannabis and CDA Clinics Australia are rapidly expanding their patient reach, bringing an excellent channel for our innovative products,” said Creso cofounder and CEO Dr Miri Halperin Wernli.

Burleigh Heads Cannabis is a fully licensed medical cannabis wholesaler throughout Australia, while its sister company CDA Clinics is a doctor-led medical cannabis-focused chain of clinics in the country.

CDA Clinics is one of, if not, the first clinic group to pass the key milestone of 1000 SAS B patient approvals and 1500 prescriptions since launching in October 2018.

Burleigh Heads director of operations Guy Headley says they were impressed with Creso’s commerciality and the collaborative nature in which the agreement was reached.

“We are excited to provide Creso Pharma with an avenue to market which in turn provides Australian patients and doctors with another quality product option to utilise in patient care. We look forward to working with Creso Pharma as they develop further products in the coming months.”

>> Learn more about Creso Pharma

It said recently that human health products CannaQIX®10 and CannaQIX®50 are growing steadily and four new CBD hemp-oil and hemp-seed oil based products are ready for launch: cannaQIX® NITE, cannaPEAL® and cannaPEAL®NITE for helping with stress and sleep, and cannaDOL® Revitalise, a functional topical gel for muscle pin relief and joints revitalisation.

Its pot-for-pets lines has secured a commercialisation deal with European giant Virbac and is proving to be a financial hit for the company.

>> Now watch: VIDEO: The World Health Organisation recommends easing pot classification


This story was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.
This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.